$XCUR News

Last published 1d ago

1d agoXCURExicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 BillionGlobeNewswireExicure agreed to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion, subject to closing conditions.
1mo agoXCURExicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity RequirementGlobeNewswireWILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced that, on September 10, 2026, it received a letter from the Listing
3mo agoXCURExicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity IssuanceGlobeNewswireWILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR
4mo agoXCURExicure Announces Board and Committee ChangesGlobeNewswireWILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions
5mo agoXCURExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementGlobeNewswireWILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock
5mo agoXCURExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QGlobeNewswireREDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock
6mo agoXCURExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)GlobeNewswireCHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology
7mo agoXCURSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsGlobeNewswireREDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO:
7mo agoXCURExicure, Inc. Reports Full Year 2025 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash
9mo agoXCURExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantGlobeNewswireREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results
9mo agoXCURExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsGlobeNewswireREDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a
11mo agoXCURExicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual MeetingGlobeNewswireREDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its
1y agoXCURExicure, Inc. Reports Third Quarter 2025 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025
1y agoXCURNew Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual MeetingGlobeNewswireREDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its
1y agoXCURExicure Highlights Recent Achievements and Near-term Strategic PrioritiesGlobeNewswireBurixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise
1y agoXCURExicure, Inc. Reports Second Quarter 2025 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were
1y agoXCURExicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance
1y agoXCURExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantBusiness WireTopline results expected H2 2025 Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in
1y agoXCURExicure, Inc. Reports First Quarter 2025 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were
1y agoXCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2025 notifying the Company that, as a result of the
1y agoXCURExicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantBusiness WireTopline results expected H2 2025 Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing
1y agoXCURExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaBusiness WireExicure, Inc. (NASDAQ:XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule
1y agoXCURExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)Business WireExicure, Inc. (NASDAQ:XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid Leukemia (AML) with
1y agoXCURExicure, Inc. Reports Full Year 2024 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
1y agoXCURExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaBusiness WireExicure, Inc. (NASDAQ:XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company's innovative
1y agoXCURExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.Business WireExicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation
1y agoXCURExicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in BiotechBusiness WireExicure, Inc. (NASDAQ:XCUR, "Exicure", "the Company")), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the acquisition
1y agoXCURExicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board ChangesBusiness WireExicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17,
1y agoXCURExicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR, the ", Company", )) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In
2y agoXCURExicure, Inc. Receives Extension from Nasdaq Hearings PanelBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel ("Panel") granted an extension to continue the Company's
2y agoXCURExicure, Inc. Announces 1-for-5 Reverse Stock SplitBusiness WireExicure, Inc. (NASDAQ:XCUR, "the Company")) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Company expects that the Reverse
2y agoXCURExicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special MeetingBusiness WireExicure, Inc. (NASDAQ:XCUR, the ", Company", )) announced today that its Special Meeting of Stockholders (the "Special Meeting"), initially scheduled for August 15, 2024 and adjourned and reconvened on
2y agoXCURExicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special MeetingBusiness WireExicure, Inc. (NASDAQ:XCUR, the ", Company", )) announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has been adjourned for the
2y agoXCURExicure, Inc. Reports Second Quarter 2024 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR, the ", Company", )), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In
2y agoXCURExicure, Inc. Recruits Head of Corporate Development and BioinformaticsBusiness WireAnna Chukaeva has been appointed as Senior Vice President, Head of Corporate Development and Bioinformatics of Exicure, Inc. ("the Company") (NASDAQ:XCUR). Anna will spearhead investments, acquisitions, and strategic
2y agoXCURExicure, Inc. Receives Positive Listing Determination from NasdaqBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today that on July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel ("Panel") has determined to continue the Company's
2y agoXCURExicure, Inc. Reports First Quarter 2024 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR, the "Company")), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September
2y agoXCURExicure, Inc. Reports Full Year 2023 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
2y agoXCURExicure, Inc. Received Nasdaq Notice of a Delisting DeterminationBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received notice of a delisting determination (the "Staff Delisting Determination") from the Listing Qualifications Department of The Nasdaq
2y agoXCURExicure, Inc. Reports Third Quarter 2023 Financial ResultsBusiness WireExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
2y agoXCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the
2y agoXCURExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisBusiness WireExicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases,
2y agoXCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 22, 2023 notifying the Company that, as a result of
3y agoXCURExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsBusiness WireExicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of
3y agoXCURExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateBusiness WireExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
3y agoXCURExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateBusiness WireExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company
3y agoXCURExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic AlternativesBusiness WireExicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously
3y agoXCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QBusiness WireExicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 17, 2023 notifying the Company that, as a result of the
3y agoXCURExicure, Inc. Announces Investment in Korean SNS Platform CyworldBusiness WireExicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it has invested in
3y agoXCURExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsBusiness WireExicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of